MMS
Regulatory compliance and data solutions provider
Clinical Data Associate
About the job
- A Bachelor's Degree in a scientific, medical, or clinical discipline or related field is required.
- One to two years of previous experience in clinical data management.
- Experience in the pharmaceutical or contract research organization industry is required.
- Experience with query and discrepancy management is required.
- Gain experience with Microsoft Office applications.
- Learn ICH, 21 CFR Part 11, ISO 9001, and ISO 7001.
- Gain exposure to electronic case report forms, CRF Completion Guidelines, edit check specifications, and data management plans.
- Contribute to study tracking and metric reports for use by the study team.
- Contribute to user acceptance testing of electronic data capture and integrated systems, including execution of test plans and scripts.
- Serve as a member of the project team.
- Hands-on experience with clinical trials and pharmaceutical development.
- A Master's or PhD.
About the company
MMS Holdings is a global contract research organization (CRO) focused on regulatory compliance and data-driven solutions for pharmaceutical and biotech sponsors. It delivers services such as regulatory submissions, clinical trial management, data analytics, and medical writing through a service-based model that relies on established processes and experienced advisors. Its work is contract-based, often long-term, aimed at helping clients meet regulatory requirements, run trials efficiently, and advance therapies under FDA guidance. The company differentiates itself with a science-first approach, a strong track record (97% client satisfaction), and involvement in complex areas like enabling MDMA-assisted therapy research, underscoring a commitment to high-quality, compliant outcomes for sponsors globally.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Canton, Michigan
Founded
2006
Get referred to MMS
See people who can refer or advise you
Simplify's Take
What believers are saying
- June 8, 2026 West Coast expansion targets biotech hubs ahead of BIO 2026.
- MMS added BI and BD leaders in 2026, signaling demand and pipeline momentum.
- I-ACT partnership and pediatric-trial work broaden access to mission-critical sponsor programs.
What critics are saying
- Large CROs like IQVIA and Parexel pressure pricing across biometrics and submissions.
- Exploristics integration can distract teams and delay promised European cross-sell through 2026.
- One pivotal trial data error or submission miss would destroy sponsor trust and future awards.
What makes MMS unique
- MMS paired Exploristics' KerusCloud with biometrics after the February 2025 acquisition.
- Ben Dudley became president on May 12, 2026, sharpening commercial execution.
- FDA-experienced hires Somya Dunn and Stephine Keeton deepen regulatory and safety expertise.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 21%1 year growth
↑ 21%2 year growth
↑ 21%MMS, a clinical research organization, has acquired Exploristics, a biostatistics and data science company. This acquisition enhances MMS' capabilities in advanced clinical trial design and data science, integrating Exploristics' KerusCloud® platform. The move expands MMS' global presence, particularly in Europe, and aims to optimize drug development strategies, reducing time and costs. Exploristics' CEO, Aiden Flynn, joins MMS as Senior VP, Head of Strategic Statistical Consulting.
On January 29, 2024, Orgenesis Inc. acquired all equity interests in Octomera LLC from MM OS Holdings, L.P., an affiliate of Metalmark Capital.
MMS Holdings Inc. plan to expand and grow in the UK and Europe to build on its teams and deliver value to its clients”
EmVenio Research announced the appointment of Mark Mackenzie, MD, as chief medical officer.
MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors.